9 Meters Biopharma Inc (NMTR)


Stock Price Forecast

Aug. 4, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading 9 Meters Biopharma Inc chart...

About the Company

9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.

$0M

Total Revenue

18

Employees

$0M

Market Capitalization

0.00

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NMTR News

9 Meters Biopharma, Inc. (NMTRQ)

8d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome

1y ago, source: pharmaphorum

Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome ...

Nissim Darvish's Net Worth

1mon ago, source: Benzinga.com

This is based on reported shares across multiple companies, which include 9 METERS BIOPHARMA, INC., and Chemomab Therapeutics Ltd.. Attention insiders: Dive deeper into market movements and stay ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript

11d ago, source: Hosted on MSN

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript March ... In 2023, we successfully advanced this business and generated over $10 million in total revenue. I'm going to ...

ABVC BioPharma, Inc. Common Stock (ABVC)

4y ago, source: Nasdaq

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript

20d ago, source: Yahoo Finance

Theravance Biopharma ... I’m pleased to report that our team delivered on these objectives. For both the fourth quarter and the full year, we increased the YUPELRI net sales 9% from $61 million ...

Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024

13d ago, source: Stockhouse

March 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus&CloseCurlyDoubleQuote ... will present at the Leerink Partners Global Biopharma Conference 2024 at 9:20 a.m. ET on Tuesday, March ...

9 Meters Biopharma Inc (NMTRQ)

1mon ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

9 Meters Biopharma Inc. (NMTRQ)

6mon ago, source: Nasdaq

*The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. It is possible that this date will be updated in the future, once the company announces ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...